Over the last decade, the results of numerous large cardiovascular outcome trials in patients with diabetes at high cardiovascular risk with novel glucose-lowering medications, such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have substantially offered more available medications, resulting in brand new evidence-based medical therapy for the management of this population (Marx et al., 2023). The gene discussed is GLP1R; the disease is diabetes mellitus.